The Business of Biofabrication

A Lyon-based CRDMO is betting that automated, patient-specific microtumors can fix the broken economics of cancer drug development. The French state just bought in.

Ninety-five percent of new cancer drugs fail in human clinical trials. That single number, recited in every oncology pitch deck for the better part of a decade, is the foundation under a €2.46 million bet now backed by the French government.

CTIBIOTECH, a contract research, development, and manufacturing organization (CRDMO) operating out of Meyzieu near Lyon, has secured €1.25 million from Bpifrance under the Aide au Développement Deeptech program, with strategic backing from France 2030. The capital launches CTIONCOTEST™, a 36-month program to take 3D bioprinted patient-derived microtumors from working prototype (TRL 5) to high-throughput commercial product (TRL 8) by 2029.

If it works, it’s not a research curiosity. It’s a de-risking platform that biopharma can actually buy.

Why this matters for the industry

The preclinical predictivity gap is one of the most expensive problems in pharma. Drugs that look promising in 2D cell culture and mouse models routinely collapse in Phase II and Phase III, and oncology is the worst offender. The industry has known for years that better human models would save billions, what’s been missing is a way to make them at scale, reproducibly, from the right patient cells.

That’s the wedge CTIBIOTECH is driving in. The CTIONCOTEST platform takes primary tumor cells from a specific cancer patient and uses computer-aided 3D bioprinting to produce hundreds of standardized microtumors that retain the architecture of the original disease, including hypoxic and necrotic zones that drive drug resistance. CTIBIOTECH says these constructs have hit 128 days of cellular viability, which is the kind of duration that opens up serious long-term studies on resistance and metastasis rather than the snapshot reads most preclinical models support.

The initial focus is breast, colon, and pancreatic cancer, three indications where reliable predictive models have been notoriously thin and where the unmet clinical need is severe.

The NAMs tailwind

CTIONCOTEST sits squarely inside a regulatory shift the entire bioprinting industry has been waiting for: the move toward New Approach Methodologies (NAMs) and away from animal testing. The FDA Modernization Act 2.0 and parallel European pressure have pulled forward demand for human-derived, ethically defensible preclinical platforms. A 100% human-derived, patient-specific testing system isn’t just scientifically appealing, it’s increasingly what regulators want to see.

For French and European biopharma, having a domestic CRDMO that can deliver this kind of platform reduces dependence on US contract research infrastructure. That alignment with sovereignty priorities is almost certainly part of why France 2030 wrote the check.

The business model is the story

What separates CTIONCOTEST from the long list of academic 3D tumor projects is the dual-revenue commercial design. CTIBIOTECH plans to sell turnkey kits, standardized, off-the-shelf microtumor panels biopharma teams can run in their own labs, alongside contract research engagements where CTIBIOTECH’s team handles bespoke studies for partners. That two-sided model is rare in the bioprinting space and arguably the most defensible play for a CRDMO: you capture the customers who want to insource and the ones who want to outsource.

The economic projections attached to the project: 5 permanent scientific hires in 2026, scaling to 51 jobs and €16 million in revenue by 2031. Operations run out of CTIBIOTECH’s 800 m² facility and certified biobank in Meyzieu.

A network, not a lab

The collaborator list reads like a deliberate ecosystem build rather than a vanity citation. The project is labeled by the Lyonbiopôle Auvergne-Rhône-Alpes competitiveness cluster, with Centre Léon Bérard (one of France’s leading comprehensive cancer centers), Hospices Civils de Lyon, Medical University Plovdiv, Transgene, GenXMap, Oncodesign Services, and Novotec all in the partnership. That network gives CTIBIOTECH something most bioprinting startups don’t have: clinical pipelines for primary tumor tissue, immuno-oncology partners, and contract research counterparts who can validate the platform in real drug development workflows.

What to watch

“The industrialization of the CTIONCOTEST platform marks a crucial step toward personalized medicine against cancer, where treatments can be individually tailored to a patient’s specific tumor profile,” said Professor Colin McGuckin, President and CSO of CTIBIOTECH.

CEO Dr. Nico Forraz framed the funding more bluntly: it lets the company “advance twice as fast” on commercialization.

The bigger question for the industry is whether CTIONCOTEST can hit the throughput and standardization targets that biopharma actually requires. “Hundreds of standardized microtumors per patient” is the promise. If the platform delivers that consistency at the price points oncology screening can absorb, CTIBIOTECH becomes one of the more interesting CRDMO stories in European biofabrication, a company positioned at the intersection of personalized medicine, NAMs adoption, and the long-overdue industrialization of patient-derived tumor models.

That’s a narrative worth tracking for the next 36 months.

---

Source: CTIBIOTECH announcement, Lyon, France.